Abstract
Interleukin-22 (IL-22) is a member of the IL-10 family of anti-inflammatory cytokines that mediates epithelial immunity. IL-22 expression is enhanced in inflamed colon mucosa in individuals with inflammatory bowel disease. We carried out an association study to examine the hypothesis that common variation in the IL-22 gene is associated with risk of colon cancer. Seven tagging SNPs were genotyped in 561 colon cancer cases and 722 population controls. Information on lifestyle risk factors was collected via a self-administered questionnaire. The rs1179251 SNP conferred an estimated odds ratio (OR) of 1.46 (95% CI = 1.04–2.05) and 2.10 (95% CI = 0.66–6.66), respectively, for those heterozygous and homozygous for the G variant (p additive = 0.013) after adjustment for age, gender, and race; the OR assuming a dominant model was 1.50 (95% CI = 1.05–2.08, p dominant = 0.016). No other SNP was statistically significantly associated with colon cancer risk. Haplotype analysis found that one haplotype containing the rs1179251 G allele gave an estimated 52% increase in risk of colon cancer for individuals with at least one copy (OR = 1.52, 95% CI = 1.12–2.06, p = 0.0073). Our findings suggest that the rs1179251 SNP in IL-22 is associated with risk of colon cancer.
Similar content being viewed by others
References
Dalgleish AG, O’Byrne K (2006) Inflammation and cancer: the role of the immune response and angiogenesis. Cancer Treat Res 130:1–38
Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183
Vivier E, Spits H, Cupedo T (2008) Interleukin-22-producing innate immune cells: new players in mucosal immunity and tissue repair? Nat Rev Immunol 9:229–234
Wu PW, Li J, Kodangattil SR et al (2008) IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22. J Mol Biol 382:1168–1183
Lejeune D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC (2002) Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 277:33676–33682
Ziesche E, Bachmann M, Kleinert H, Pfeilschifter J, Muhl H (2007) The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282:16006–16015
Andoh A, Zhang Z, Inatomi O et al (2005) Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129:969–984
Weber GF, Gaertner FC, Erl W et al (2006) IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177:8266–8272
Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G (2008) Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 14:633–637
de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D (2005) Efficiency and power in genetic association studies. Nat Genet 37:1217–1223
Aujla SJ, Chan YR, Zheng M et al (2008) IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 14:275–281
Zheng Y, Valdez PA, Danilenko DM et al (2008) Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 14:282–289
Cacev T, Radosevic S, Krizanac S, Kapitanovic S (2008) Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis 29:1572–1580
Poole C (1999) Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am J Epidemiol 150:547–551
Thompson CL, Plummer SJ, Acheson LS, Tucker TC, Casey G, Li L (2009) Association of common genetic variants in SMAD7 and risk of colon cancer. Carcinogenesis 30:982–986
Li L, Plummer SJ, Thompson CL et al (2008) A common 8q24 variant and the risk of colon cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 17:339–342
Rothman KJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43–46
Conneely KN, Boehnke M (2007) So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am J Hum Genet 81:1158–1168
Acknowledgments
Supported by an R25 and K07 training grants and an R01 research grant from the National Cancer Institute (R25 CA094186, K07 CA136758, R01 CA136726), the Damon Runyon Cancer Research Foundation, Clinical Investigator Award (CI-8), Case Center for Transdisciplinary Research on Energetics and Cancer (U54 CA116867), and National Cancer Institute K22 Award (K22 CA120545). The authors wish to thank Svetlana Zelenskiy for her assistance in constructing the tables.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Thompson, C.L., Plummer, S.J., Tucker, T.C. et al. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 21, 1165–1170 (2010). https://doi.org/10.1007/s10552-010-9542-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-010-9542-5